|
Home : Unsafe Drugs : Avandia : Newsfeeds : Merck's first quarter profit surges on lower merger-related costs, sales of diabetes drug Januvia up in Europe Merck's first quarter profit surges on lower merger-related costs, sales of diabetes drug Januvia up in Europe
Adam Schechter, who heads Merck’s global pharmaceutical business, said the jump in sales of Januvia occurred as a result of Merck’s strategic move in Europe last year after the diabetes drug Avandia was pulled from the market. “We moved quickly and ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




